Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 11/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.34 |
| ▸ | CA6 | P23280 | 1/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.34 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18873290 | 0.86 | ERN1 (0.47) | ERN1KDM4EPTGS2RAB9APADI4 | |
| SCHEMBL455552 | 0.82 | ERN1 (0.47) | ERN1KDM4EPTGS2RAB9APADI4 | |
| SCHEMBL1955946 | 0.82 | ERN1 (0.44) | ERN1CYP2C9CYP3A4CYP2C19KDM4E | |
| SCHEMBL31685229 | 0.80 | CYP2C9 (0.46) | ERN1CYP2C9CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL415893 | 0.80 | CYP2C9 (0.46) | ERN1CYP2C9CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL24677699 | 0.78 | ERN1 (0.46) | ERN1CYP3A4KDM4EPTGS2RAB9A | |
| SCHEMBL2252231 | 0.78 | ERN1 (0.44) | ERN1CYP3A4KDM4EPTGS2RAB9A | |
| SCHEMBL30134282 | 0.78 | ERN1 (0.46) | ERN1CYP3A4KDM4EPTGS2RAB9A | |
| SCHEMBL22445291 | 0.78 | ERN1 (0.41) | ERN1CYP2C9CYP3A4CYP2C19KDM4E | |
| SCHEMBL566230 | 0.78 | ERN1 (0.46) | ERN1KDM4EPTGS2RAB9APADI4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132111-A1 | Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics | PROSETTA BIOSCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12503455-B2 | Nucleic acid-binding photoprobes and uses thereof | ARRAKIS THERAPEUTICS, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250353874-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | LILLY CO ELI (US) | 2025-11-20 | — | — | US | disclosed |
| US-12459901-B2 | Host-targeted pan-respiratory antiviral small molecule therapeutics | PROSETTA BIOSCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-12404298-B2 | Glucocorticoid receptor agonists | ELI LILLY AND COMPANY (US) | 2025-09-02 | — | — | US | disclosed |
| EP-4402124-A1 | NOVEL HOST-TARGETED PAN-RESPIRATORY ANTIVIRAL SMALL MOLECULE THERAPEUTICS | Prosetta Biosciences, Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| US-12017997-B2 | Host-targeted pan-respiratory antiviral small molecule therapeutics | PROSETTA BIOSCIENCES, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240190826-A1 | Novel Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics | PROSETTA BIOSCIENCES, INC. | 2024-06-13 | — | — | US | disclosed |
| US-20240018182-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | ELI LILLY AND COMPANY | 2024-01-18 | — | — | US | disclosed |
| US-11807623-B2 | Nucleic acid-binding photoprobes and uses thereof | ARRAKIS THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON INC. | 2010-09-30 | — | — | US | disclosed |
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON INC. | 2010-09-30 | — | — | US | disclosed |
| EP-2155747-A1 | IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS | Acadia Pharmaceuticals Inc. (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008141249-A1 | IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008141239-A1 | IMIDAZOL [1,2-A] PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| EP-1893612-A1 | PYRROLO [2, 3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2007002325-A1 | PYRROLO[2,3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002325-A1 | PYRROLO[2,3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002433-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002433-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | MAP4K1, MAP4K2, MAP3K1 | ERN1 252/4885CYP2C9 4869/4885CYP3A4 4851/4885 |
| US-20260132111-A1 | Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics | NCOR1, HAVCR2, NR3C1 | ERN1 942/4885CYP2C9 2444/4885CYP3A4 1969/4885 |
| US-12017997-B2 | Host-targeted pan-respiratory antiviral small molecule therapeutics | MAVS, SARS1, ZC3HAV1 | ERN1 593/4885CYP2C9 4584/4885CYP3A4 3718/4885 |
| US-20240190826-A1 | Novel Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics | MAVS, SARS1, ZC3HAV1 | ERN1 585/4885CYP2C9 4465/4885CYP3A4 3601/4885 |
| US-12404298-B2 | Glucocorticoid receptor agonists | NR3C1, NR3C2, MC2R | ERN1 1650/4885CYP2C9 919/4885CYP3A4 911/4885 |
| US-20240018182-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | NR3C1, NR3C2, MC2R | ERN1 1650/4885CYP2C9 919/4885CYP3A4 911/4885 |
| US-20250353874-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | NR3C1, NR3C2, MC2R | ERN1 1650/4885CYP2C9 919/4885CYP3A4 911/4885 |
| US-12503455-B2 | Nucleic acid-binding photoprobes and uses thereof | NSUN3, NSUN2, TARBP1 | ERN1 877/4885CYP2C9 2710/4885CYP3A4 1987/4885 |
| US-12459901-B2 | Host-targeted pan-respiratory antiviral small molecule therapeutics | MAVS, SARS1, ZC3HAV1 | ERN1 593/4885CYP2C9 4584/4885CYP3A4 3718/4885 |
| US-11807623-B2 | Nucleic acid-binding photoprobes and uses thereof | NSUN3, NSUN2, TARBP1 | ERN1 877/4885CYP2C9 2710/4885CYP3A4 1987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.